Skip to content
MRD Watch

Wednesday, November 18, 2026

Subscribe
Sponsor this briefing. One site and newsletter slot, $250/week.

Briefing

Molecular residual disease (MRD) analysis from the LAURA study of osimertinib in unresectable stage III EGFR-mutated NSCLC

ESMO Congress 2025